Literature DB >> 16944355

Scales in Parkinson's disease.

Georg Ebersbach1, Horst Baas, Ilona Csoti, Martina Müngersdorf, Günther Deuschl.   

Abstract

The search for valid instruments to measure different domains of health disturbances becomes increasingly important for the assessment of Parkinson's disease. The most widely used tool is the Unified Parkinson's Disease Rating Scale (UPDRS) which was introduced in 1987 and is currently awaiting revision. In addition, a variety of instruments have been used to capture non-motor aspects of Parkinson's disease but only a minority of these instruments has been validated for this particular disease condition. Measurements of quality of life are being incorporated into an increasing number of studies in order to reflect a more integral view of health and have contributed to a better understanding of the impact of disease and interventions. The International Classification of Functioning, Disability and Health introduced by the WHO in 2001 offers a multidimensional approach to human functioning and participation that can also be applied to the assessment of health status in PD. This workshop report will focus on the present state of clinimetry in PD and discuss future perspectives.

Entities:  

Mesh:

Year:  2006        PMID: 16944355     DOI: 10.1007/s00415-006-4008-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

Authors:  A D Korczyn; E R Brunt; J P Larsen; Z Nagy; W H Poewe; S Ruggieri
Journal:  Neurology       Date:  1999-07-22       Impact factor: 9.910

2.  International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.

Authors:  Kallol Ray Chaudhuri; Pablo Martinez-Martin; Anthony H V Schapira; Fabrizio Stocchi; Kapil Sethi; Per Odin; Richard G Brown; William Koller; Paolo Barone; Graeme MacPhee; Linda Kelly; Martin Rabey; Doug MacMahon; Sue Thomas; William Ondo; David Rye; Alison Forbes; Susanne Tluk; Vandana Dhawan; Annette Bowron; Adrian J Williams; Charles W Olanow
Journal:  Mov Disord       Date:  2006-07       Impact factor: 10.338

3.  Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.

Authors:  H Reichmann; J Boas; D Macmahon; V Myllyla; A Hakala; K Reinikainen
Journal:  Acta Neurol Scand       Date:  2005-01       Impact factor: 3.209

4.  How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population.

Authors:  A Schrag; M Jahanshahi; N Quinn
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

5.  Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.

Authors:  O Rascol; D J Brooks; E R Brunt; A D Korczyn; W H Poewe; F Stocchi
Journal:  Mov Disord       Date:  1998-01       Impact factor: 10.338

6.  What contributes to quality of life in patients with Parkinson's disease?

Authors:  A Schrag; M Jahanshahi; N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

7.  Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

Authors:  W H Poewe; G Deuschl; A Gordin; E-R Kultalahti; M Leinonen
Journal:  Acta Neurol Scand       Date:  2002-04       Impact factor: 3.209

8.  Teaching tape for the motor section of the unified Parkinson's disease rating scale.

Authors:  C G Goetz; G T Stebbins; T A Chmura; S Fahn; H L Klawans; C D Marsden
Journal:  Mov Disord       Date:  1995-05       Impact factor: 10.338

9.  Systematic evaluation of rating scales for impairment and disability in Parkinson's disease.

Authors:  Claudia Ramaker; Johan Marinus; Anne Margarethe Stiggelbout; Bob Johannes Van Hilten
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

10.  Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.

Authors:  Connie Marras; Anthony Lang; Murray Krahn; George Tomlinson; Gary Naglie
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338

View more
  26 in total

1.  Decrease in gait variability while counting backward: a marker of "magnet effect"?

Authors:  O Beauchet; G Allali; L Poujol; J C Barthelemy; F Roche; C Annweiler
Journal:  J Neural Transm (Vienna)       Date:  2010-08-31       Impact factor: 3.575

Review 2.  Potential of APDM mobility lab for the monitoring of the progression of Parkinson's disease.

Authors:  Martina Mancini; Fay B Horak
Journal:  Expert Rev Med Devices       Date:  2016-05       Impact factor: 3.166

3.  Mobility Lab to Assess Balance and Gait with Synchronized Body-worn Sensors.

Authors:  Martina Mancini; Laurie King; Arash Salarian; Lars Holmstrom; James McNames; Fay B Horak
Journal:  J Bioeng Biomed Sci       Date:  2011-12-12

4.  Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer's disease.

Authors:  Olivier Beauchet; Cyrille P Launay; Gilles Allali; François R Herrmann; Cedric Annweiler
Journal:  Drugs Aging       Date:  2014-05       Impact factor: 3.923

5.  Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.

Authors:  D James Surmeier; Jack T Nguyen; Nicola Lancki; Charles S Venuto; David Oakes; Tanya Simuni; Richard K Wyse
Journal:  Mov Disord       Date:  2021-11-12       Impact factor: 10.338

6.  Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial.

Authors:  Olivier Beauchet; John Barden; Teresa Liu-Ambrose; Victoria L Chester; Cedric Annweiler; Tony Szturm; Sébastien Grenier; Guillaume Léonard; Louis Bherer; Gilles Allali
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

7.  The Unified Parkinson's Disease Rating Scale as a predictor of peak aerobic capacity and ambulatory function.

Authors:  Frederick M Ivey; Leslie I Katzel; John D Sorkin; Richard F Macko; Lisa M Shulman
Journal:  J Rehabil Res Dev       Date:  2012

8.  The impact of distinct cognitive dual-tasks on gait in Parkinson's disease and the associations with the clinical features of Parkinson's disease.

Authors:  Halil Onder; Ozge Ozyurek
Journal:  Neurol Sci       Date:  2020-11-04       Impact factor: 3.307

9.  Enhancing Quality of Life in Indian Parkinson's Disease Patients with Improved Measurement of Psychological Domains: A Perspective.

Authors:  Ashima Nehra; Priya Sharma; Avneesh Narain; Shivani Sharma; Garima Joshi; Priyanka Bhat; Rajesh Kumar Singh; Roopa Rajan; Vinay Goyal; Achal Kumar Srivastava
Journal:  Ann Indian Acad Neurol       Date:  2021-04-10       Impact factor: 1.383

10.  ISway: a sensitive, valid and reliable measure of postural control.

Authors:  Martina Mancini; Arash Salarian; Patricia Carlson-Kuhta; Cris Zampieri; Laurie King; Lorenzo Chiari; Fay B Horak
Journal:  J Neuroeng Rehabil       Date:  2012-08-22       Impact factor: 4.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.